Animal Researche: 18pt;">Non-psychoactive cannabis compound CBD may help people quit everything from smoking to opioids, and possibly even alcohol.
CBD is one of the main therapeutic compounds found in cannabis plants. CBD has been suggested to help with drug addiction by:
- Influencing brain systems involved in drug addiction, such as neurotransmitters, the amygdala, and the endocannabinoid system.
Cannabidiol (CBD) is one of more than 60 cannabinoids – natural compounds responsible for the medicinal benefits of cannabis. CBD is the second-most abundant cannabinoid after tetrahydrocannabinol (THC).
Unlike THC, CBD does not make you high, making it ideal for reaping the benefits of cannabis without any of the mind-altering effects. As a result, CBD has rapidly grown in popularity as a supplement for a wide range of conditions, including anxiety, chronic pain, arthritis, insomnia, Alzheimer’s, and epilepsy.
In addition, an increasing amount of research evidence points to the usefulness of CBD in helping with drug addiction. Early studies suggest that CBD can reduce cravings for a wide range of substances including tobacco, cannabis, psychostimulants, and opioids. In fact, CBD may even help people quit drinking.
Although CBD does not have any strong interaction with the two known ECS receptors (CB1 & CB2), it does influence the GPR55 receptor, believed by many scientists to be the third (CB3) cannabinoid receptor, and could affect other novel cannabinoid receptors.2
In addition, CBD can indirectly influence the ECS by increasing levels of anandamide – the main endocannabinoid made inside the human body. This effect may be particularly involved in CBD’s ability to relieve cannabis addiction and withdrawal. 3
In addition, CBD as been demonstrated to affect regions of the brain implicated in addiction and negative affectivity. Most notably, CBD has been shown to reduce activity of the amygdala – the brain structure which controls anxiety, stress, and emotional processing, and is involved in addiction. 5
Preclinical and early human studies support these uses, and suggest that CBD can help with alcohol, opioid, cocaine, psychostimulant, cannabis, and tobacco addiction. Furthermore, there is evidence that CBD can also alleviate withdrawal symptoms associated with cannabis.
But although this research is promising, more human studies are needed to fully examine CBD’s potential as a remedy for drug addiction.
Animal and isolated cell culture studies of CBD demonstrate beneficial effects on substance addiction. Specific findings indicate that:
- CBD skin patches given to rats with a history of alcohol or cocaine consumption reduced drug seeking behavior, suggesting the use of CBD for preventing alcohol and cocaine relapse 7
- CBD interferes with brain reward systems involved in opioid addiction in rats 8
- CBD reduces heroin cravings/seeking in rats 9
- CBD removes conditioned place preference (CPP) for cocaine and amphetamine in rats, which could help with cravings and relapse 10
This randomized, double-blind, placebo-controlled, pilot study examined the effects of CBD on smokers who were trying to quit. A total of 24 smokers were given a placebo or CBD-containing (400 mcg per dose) inhaler for one week, and were told to use it when they felt the urge to smoke. Whereas placebo had no effect, CBD resulted in a 40% reduction of cigarettes smoked during the treatment, and some of this reduction was maintained afterwards as well.
- The researchers concluded that “These preliminary data, combined with the strong preclinical rationale for use of this compound, suggest CBD to be a potential treatment for nicotine addiction…” 11
This report looked at the case of a 19-year-old woman who suffered from cannabis withdrawal syndrome. She took CBD (300-600 mg) for 10 days, resulting in the dissappearance of significant signs of withdrawal, such as anxiety and dissociative symptoms.
- The researchers concluded that “CBD can be effective for the treatment of cannabis withdrawal syndrome.” 12
This randomized, double-blind, placebo-controlled study examined the effects of CBD on heroin addiction. Heroin addicts were given CBD (400 or 800 mg) or placebo for 3 days. Their opioid cravings were tested 1 hour and 24 hours after a single CBD or placebo dose, and 7 days after the final CBD or placebo dose. Compared to placebo, CBD significantly reduced heroin cravings, an effect which persisted for 7 days after the treatment was over.
- The researchers concluded that “These preliminary pilot human study findings support…potential therapeutic efficacy of CBD to reduce negative states in opioid-dependent individuals, which may, in turn…reduce the likelihood of relapse behavior.” 13
This study examined the effects of CBD: THC ratio on the addictive properties of cannabis. A total of 94 cannabis smokers were tested drug-free and when high on cannabis on measures of drug (cannabis) dependence. The study discovered that smokers of high-CBD marijuana strains performed better on tests and ratings of cannabis addiction, most notably having reduced attentional bias to drugs and food.
- The researchers concluded that “…CBD has potential as a treatment for cannabis dependence.” 14
We recommend trying CBD for substance addiction. Whether it’s alcohol, smoking, or more serious addictions such as opioids, current research evidence supports CBD’s ability to help people quit a wide range of substances. Having said that, more clinical studies are needed to fully document CBD’s potential.
There is no established CBD dosage for drug addiction. Given the scarcity of research it is best to start with 15+ mg dosages recommended by most CBD supplements, after which you can increase the dosage until you feel the desired effect.
- Maldonado R et al. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006 Apr;29(4):225-32. ↩
- Schuelert N and McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett. 2011 Aug 1;500(1):72-6. ↩
- Deutsch DG. A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). Front Pharmacol. 2016 Oct 13;7:370. eCollection 2016. ↩
- Campos AC et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016 Oct;112:119-127. ↩
- Hsiao YT et al. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012 Jan;62(1):373-84. ↩
- Yasmin L. Hurd. Cannabidiol: Swinging the Marijuana Pendulum From ‘Weed’ to Medication to Treat the Opioid Epidemic. Trends in Neurosciences , Volume 40 , Issue 3 , 124 – 127 ↩
- Loren H. Parsons et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology (2018). ↩
- Katsidoni V et al. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol. 2013 Mar;18(2):286-96. ↩
- Ren Y et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009 Nov 25;29(47):14764-9. ↩
- Parker LA et al. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl). 2004 Sep;175(3):360-6. ↩
- Morgan CJ et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013 Sep;38(9):2433-6. ↩
- Crippa JA et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013 Apr;38(2):162-4. ↩
- Hurd YL et al. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015 Oct;12(4):807-15. ↩
- Morgan CJ et al. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010 Aug;35(9):1879-85. ↩